Orchestra BioMed Holdings (OBIO) Change in Cash (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Change in Cash data on file, last reported at -$6.3 million in Q1 2026.

• Quarterly Change in Cash fell 61.59% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 301.35% YoY) and the FY2025 annual result came in at $12.4 million, up 249.78% from the prior year.
• Change in Cash advanced to -$6.3 million in Q1 2026 per OBIO's latest filing, from -$7.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $77.6 million in Q2 2022 and bottomed at -$77.2 million in Q4 2022.
• The 5-year median for Change in Cash is -$1.1 million (2023), against an average of $1.1 million.
• Peak annual rise in Change in Cash reached 198454.75% in 2022, while the deepest fall reached 267668.34% in 2022.
• Tracing OBIO's Change in Cash over 5 years: stood at -$77.2 million in 2022, then surged by 114.87% to $11.5 million in 2023, then slumped by 129.13% to -$3.3 million in 2024, then sank by 118.96% to -$7.3 million in 2025, then advanced by 13.64% to -$6.3 million in 2026.
• Per Business Quant, the three latest OBIO Change in Cash figures stand at -$6.3 million (Q1 2026), -$7.3 million (Q4 2025), and $23.3 million (Q3 2025).

Peer Comparison